First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia

Introduction. The addition of durvalumab after chemoradiation therapy in unresectable stage III non-small-cell lung cancer (NSLC) is a new standard of care.

Aim. Study the features and outcomes of durvalumab maintenance treatment after chemoradiotherapy in patients with unresectable stage III NSCLC in the real-world clinical practice in Russia.

Materials and methods. 50 patients with unresectable III stage NSCLC after concurrent or sequential chemoradiotherapy (CRT) were enrolled in this observational retrospective study. Median follow up time at primary analysis was 12.4 months.

Results. A mean age of the patients in the study was 61.2 years (58.4-64.1; 95% CI). Most of the patients had received sequential CRT (76%, n = 38). Median time of durvalumab start from the end of CRT varied from 22 to 50 days (overall - 35 days). Estimated median PFS and OS were 10.86 months (7.78-14.01, 95% CI) and 26 months (20.19-31.81, 95% CI), respectively. There was a trend toward increased PFS in patients with smoking history: 12 months (9.79-14.2; 95% CI) versus 4,9 months (0.0-12.47; 95% CI), p = 0.2. Half of the patients without smoking history (5/10) had targetable mutations (EGFR ex 19, ALK, ROS1, cMET). Most common reported adverse events of special interest were pneumonitis grade 1-2 (36%, n = 18), leading permanent treatment discontinuation to in 6% of patients (n = 3). There were no reported cases of grade 3-4 adverse events.

Conclusions. Real-world characteristic of patients in our study were different from PACIFIC trial. Sequential CRT is the most frequent treatment option in locally advanced unresectable NSCLC in Russia. Estimated PFS was shorter than in PACIFIC, but there were less cases of pneumonitis.

1. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933. https://doi.org/10.1200/JCO.2017.74.3062.

2. Antonia SJ., Borghaei H., Ramalingam S.S., Horn L., De Castro Carpeno J., Pluzanski A. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395-1408. https://doi.org/10.1016/S1470-2045(19)30407-3.

3. Herbst R.S., Baas P., Kim D.W., Felip E., Perez-Gracia J.L., Han J.Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7.

4. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. https://doi.org/10.1016/S0140-6736(16)32517-X.

5. Goldstraw P., Chansky K., Crowley J., Rami-Porta R., Asamura H., Eberhardt W.E. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. https://doi.org/10.1016/j.jtho.2015.09.009.

6. Jazieh A.R., Onal H.C., Tan D.S.W., Soo R.A., Prabhash K., Kumar A. et al. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. J Thorac Oncol. 2021;16(10):1733-1744. https://doi.org/10.1016/j.jtho.2021.05.003.

7. Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J.F. et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-867. https://doi.org/10.1016/j.jtho.2020.12.015.

8. Spigel D., Faivre-Finn C., Gray J., Vicente D., Planchard D., Paz-Ares L. et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol. 2021;39(Suppl. 15):8511. https://doi.org/10.1200/JCO.2021.39.15_suppl.8511.

9. Laktionov K.K., Artamonova E.V., Borisova T.N., Breder V.V., Bychkov Yu.M., Vladimirova L.Yu. et al. Malignant neoplasm of the bronchi and lung: clinical recommendations. Moscow; 2021. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/30_3.

10. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. https://doi.org/10.1016/j.ejca.2008.10.026.

11. Yukalchuk D.Yu., Ponomarenko D.M., Dvornichenko V.V., Novopashin A.M. Experience of using durvalumab in unresectable stage III non-small cell lung cancer in Irkutsk Region. Medical Alphabet. 2019;(28):5-8. (In Russ.) Available at: https://www.med-alphabet.com/jour/article/view/1193.

12. Sakaeva D.D., Ruchkin V.V., Goncharova O.V., Abbasova R.R., Mufazalov F.F. Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice. Journal of Modern Oncology. 2019;(3):21-25. (In Russ.) https://doi.org/10.26442/18151434.2019.3.190679.

13. Garassino M.C., Mazieres J., Reck M., Chouaid C., Bischoff H., Reinmuth N. et al. Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in Stage III, unresectable NSCLC (PACIFIC-6). Ann Oncol. 2022;33(Suppl. 2):S81-S82. https://doi.org/10.1016/annonc.2022.02.135.

14. Girard N., Smit H.J.M., Sibille A., McDonald F., Mornex F., Garassino M.C.C. et al. 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 2021;32(5):S939-S940. https://doi.org/10.1016/annonc.2021.08.1774.

15. Bradley J.D., Hu C., Komaki R.R., Masters G.A., Blumenschein G.R., Schild S.E. et al. Long-Term Results of NRG Oncology RTOG 0617: Standard-Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(7):706-714. https://doi.org/10.1200/JCO.19.01162.

16. O'Rourke N., Roque I. Figuls M., Farre Bernado N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;(6):CD002140. https://doi.org/10.1002/14651858.CD002140.pub3.

17. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P. et al. Metaanalysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-2190. https://doi.org/10.1200/JCO.2009.26.2543.

18. Faehling M., Schumann C., Christopoulos P., Hoffknecht P., Alt J., Horn M. et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114-122. https://doi.org/10.1016/j.lungcan.2020.10.006.

19. Park S.E., Noh J.M., Kim Y.J., Lee H.S., Cho J.H., Lim S.W. et al. EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Cancer Res Treat. 2019;51(2):493-501. https://doi.org/10.4143/crt.2018.125.

20. Aredo J.V., Mambetsariev I., Hellyer J.A., Amini A., Neal J.W., Padda S.K. et al. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021;16(6):1030-1041.https://doi.org/10.1016/j.jtho.2021.01.1628.

21. Jung H.A., Noh J.M., Sun J.M., Lee S.H., Ahn J.S., Ahn M.J. et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-smallcell lung cancer. Lung Cancer. 2020;146:23-29. https://doi.org/10.1016/j.lungcan.2020.05.035.

22. Taugner J., Kasmann L., Eze C., Ruhle A., Tufman A., Reinmuth N. et al. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs. 2021;39(4):1189-1196. https://doi.org/10.1007/s10637-021-01091-9.

23. Grangeon M., Tomasini P., Chaleat S., Jeanson A., Souquet-Bressand M., Khobta N. et al. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2019;20(3):201-207. https://doi.org/10.1016/j.cllc.2018.10.002.